{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Health Tech Nerds Radio","title":"More effective depression treatments exist—so why aren’t they used? Everbright on TMS, esketamine, and the barriers to prescribing | Ben Kuhn","html":"","width":"100%","height":180,"duration":1507,"description":"Psychiatry still relies heavily on medication management and talk therapy, leaving many patients—especially those with treatment-resistant depression—cycling through SSRIs without response, despite FDA-approved options like TMS (approved 2008) and Spravato/esketamine (approved 2019) that show roughly twice the effectiveness versus standard treatments. \nBen Kuhn, co-founder and CEO of Everbright Health, explains why these interventions haven’t become routine in independent practices: complex, frequently changing payer eligibility criteria, provider discomfort discussing specialized treatments, onerous prior auth, and the operational/compliance burden of running a new service line. \nEverbright Health positions itself as an AI-enabled MSO partner (not an acquirer), promising implementation in ~60 days by identifying eligible patients, managing education, prior auth/billing, and operations. The conversation also covers emerging therapies (psilocybin, PTSD treatment “Prism,” remote monitoring) and growing payer interest in outcomes/value-based models, citing data suggesting up to 50% total cost-of-care reductions when treatment resistance resolves.\nFor more from Health Tech Nerds, subscribe to our weekly newsletters: https://www.healthtechnerds.com/subscribe","thumbnail_url":"https://img.transistorcdn.com/y84Rj-3Zru2TSHB3gg7QPKSw1QK5xTylJGdWYgSYt5g/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS85MmYw/N2JiYjk1MjQ4NTAy/YzJiZDg1NzYyY2E2/NmI0ZS5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}